Medical Supplies for Pandemics Act of 2021
Bill: H.R.3463 | Sponsor: Rep. Dingell, Debbie (D-MI)
Policy area: Health

Summary:
Medical Supplies for Pandemics Act of 2021
This bill requires the Department of Health and Human Services (HHS) to undertake various actions to enhance supply chain elasticity for and maintain domestic reserves of critical medical supplies for the Strategic National Stockpile.
Specifically, HHS must increase emergency stocks of supplies, geographically diversify production of supplies, and enter cooperative agreements or partnerships for purposes of supporting domestic production of supplies and replenishing supplies in the stockpile. The department's authority to enter such agreements and partnerships terminates on September 30, 2024.

To amend the Public Health Service Act to authorize the use of the 
Strategic National Stockpile to enhance medical supply chain elasticity 
   and establish and maintain domestic reserves of critical medical 
                   supplies, and for other purposes.

    Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,

SECTION 1. SHORT TITLE.

    This Act may be cited as the ``Medical Supplies for Pandemics Act 
of 2021''.

SEC. 2. SUPPLY CHAIN FLEXIBILITY MANUFACTURING PILOT.

    (a) In General.--Section 319F-2(a)(3) of the Public Health Service 
Act (42 U.S.C. 247d-6b(a)(3)) is amended--
            (1) in subparagraph (I), by striking ``and'';
            (2) in subparagraph (J), by striking the period at the end 
        and inserting ``; and''; and
            (3) by adding at the end the following new subparagraph:
                    ``(K) enhance medical supply chain elasticity and 
                establish and maintain domestic reserves of critical 
                medical supplies (including personal protective 
                equipment, ancillary medical supplies, and other 
                applicable supplies required for the administration of 
                drugs, vaccines and other biological products, and 
                other medical devices (including diagnostic tests)) 
                by--
                            ``(i) increasing emergency stock of 
                        critical medical supplies;
                            ``(ii) geographically diversifying domestic 
                        production of such medical supplies, as 
                        appropriate;
                            ``(iii) entering into cooperative 
                        agreements or partnerships with respect to 
                        manufacturing lines, facilities, and equipment 
                        for the domestic production of such medical 
                        supplies; and
                            ``(iv) managing, either directly or through 
                        cooperative agreements with manufacturers and 
                        distributors, domestic reserves established 
                        under this subparagraph by refreshing and 
                        replenishing stock of such medical supplies.''.
    (b) Reporting; Sunset.--Section 319F-2(a) of the Public Health 
Service Act (42 U.S.C. 247d-6b(a)) is amended by adding at the end the 
following:
            ``(6) Reporting.--Not later than September 30, 2022, the 
        Secretary shall submit to the Committee on Energy and Commerce 
        of the House of Representatives and the Committee on Health, 
        Education, Labor and Pensions of the Senate a report on the 
        details of each cooperative agreement or partnership entered 
        into under paragraph (3)(K), including the amount expended by 
        the Secretary on each such cooperative agreement or 
        partnership.
            ``(7) Sunset.--The authority to enter into cooperative 
        agreements or partnerships pursuant to paragraph (3)(K) shall 
        cease to be effective on September 30, 2024.''.
    (c) Funding.--Section 319F-2(f) of the Public Health Service Act 
(42 U.S.C. 247d-6b(f)) is amended by adding at the end the following:
            ``(3) Supply chain elasticity.--
                    ``(A) In general.--For the purpose of carrying out 
                subsection (a)(3)(K), there is authorized to be 
                appropriated $500,000,000 for each of fiscal years 2021 
                through 2024, to remain available until expended.
                    ``(B) Relation to other amounts.--The amount 
                authorized to be appropriated by subparagraph (A) for 
                the purpose of carrying out subsection (a)(3)(K) is in 
                addition to any other amounts available for such 
                purpose.''.
                                 <all>